2.The establishment and application of five-heart nursing service model
Xingzhi HUANG ; Chun YANG ; Guixiu LIU ; Huiling CHENG ; Juan ZHANG ; Shengrong SUN
Chinese Journal of Practical Nursing 2008;24(14):10-12
Objective To establish and apply the systemic caring and nursing model,the five-heart nursing service model. Methods The five-heart nursing service content was designed,the five-heart nursing service organization was perfected,the five-heart nursing service manual books were compiled and the satisfaction questionnaires for five-heart nursing service were designed.Three tryout departments were selected and the nursing staff was trained by human theory and five-heart nursing service amenity and flow according to the five-heart nursing service requirement. Results The patients satisfaction degree, medical entanglemant complaint and praise after the application of five-heart nursing service were greatly improved compared with those of before its application (P < 0.05). Conclusion The application of five-heart nursing service supplied systemic caring and nursing for patients and it proved effective to improve patients satisfaction degree.
4.Prospective multicenter study on syndrome differentiation-based treatment with traditional Chinese medicine for Chronic Kidney Disease (CKD3-4)
Yuan MENG ; Shengrong ZHANG ; Baoli LIU ; Jing LI ; Yiwen ZHAO ; Yu WANG ; Jing ZHAO ; Wenjing ZHAO ; Nan GE ; Yanfang YANG ; Yang LIU ; Jianwei REN ; Hong CHENG ; Jianping LIU
The Journal of Practical Medicine 2014;(16):2658-2662
Objective To study the clinical curative effect of syndrome differentiation-based treatment with traditional Chinese medicine on patient with Chronic Kidney Disease (CKD3-4). Method According to prospective multicenter randomized controlled study which was applied to the patients with CKD3-4 , the total of 339 patients were divided into two groups. To one group as standard including 167 patients ,the other including 172 patients. Chinese Traditional Patent Medicine single or combined-prescription oral treatment according to syndrome differentiation-based treatment was employed. To the other group as reference , Chinese Traditional Patent Medicine oral treatment according to experienced rule was applied. The clinical curative effect results were obtained after a 24 weeks-treatment. Result The Scr ,eGFR and UTP with CKD3 in standard group illustrate statistics significance (P<0.05). On the opposite, those of the reference group remain insignificance (P > 0.05). The clinical curative effect result of patient in standard group was better than that of reference group. About the clinical curative effect of CKD4, no statistics significance difference (P > 0.05) could be found between groups or between patients in one group. The TCM score of patient with CKD3-4 in standard group have improved (P < 0.05) according to baseline. However, that of reference group did not show any statistics significance (P > 0.05). Conclusion Syndrome differentiation-based treatment with traditional Chinese medicine illustrated a better result in protection of renal function, reduction in urinary protein and decline in TCM score than the treatment according to experienced rule.
5.HIF1A is a prognostic biomarker of breast cancer and correlates with immunocyte infiltration
OUYANG Yang ; LI Juanjuan ; TU Yi ; SUN Shengrong
Chinese Journal of Cancer Biotherapy 2022;29(4):317-326
欧阳洋,李娟娟,涂毅,孙圣荣(武汉大学人民医院 乳腺甲状腺外科,湖北 武汉 430060)
[摘 要] 目的:借助多种癌症生物信息数据库研究乳腺癌组织中缺氧诱导因子1亚基α(HIF1A)的表达水平及其与乳腺癌患者预后及肿瘤免疫细胞浸润的关系。方法:利用Oncomine、人类蛋白质图谱、基因表达谱交互式分析(GEPIA)及TCGA数据库分析HIF1A基因在乳腺癌组织中的表达及其与患者预后、临床病理特征的关系,并在中国人乳腺癌组织标本(选用2011年1月至2015年12月中国武汉大学人民医院手术切除的93例乳腺癌组织和14例良性乳腺疾病组织)中进行验证。对HIF1A高低表达组间的差异基因进行基因本体(GO)和京都基因与基因组百科全书(KEGG)富集分析,用Cibersort R软件评估HIF1A高低表达样本中免疫细胞浸润丰度差异。结果:生物信息数据显示,HIF1A在乳腺癌组织中高表达,预示着患者DFS预后更好(P<0.05)。HIF1A的表达与雌激素受体(ERP)、孕激素受体(PR)和人表皮生长因子受体2(HER2)表达相关(均P<0.05)。GO生物功能及KEGG通路富集分析结果提示,HIF1A可能参与肿瘤免疫调节等生物活动。使用Cibersort分析结果显示,HIF1A与肿瘤免疫细胞浸润之间具有相关性(均P<0.01),发现活化记忆CD4 + T细胞、M0和M1型巨噬细胞与HIF1A表达呈正相关,在乳腺癌组织中高表达,Treg细胞、活化NK细胞、M2型巨噬细胞与HIF1A表达呈负相关(均P<0.01)。结论:HIF1A参与调节肿瘤微环境的免疫活性,与乳腺癌患者DFS相关,其可能成为乳腺癌分级诊断、免疫治疗和预后判断的生物标志物。
6.Bone marrow mesenchymal stem cells exosome miR-126-3p targets CCR1 to inhibit the malignant proliferation and metastasis of non-small cell lung cancer cells
Kun DU ; Bing WANG ; Shengrong YANG ; Yujie LUO ; Yunhe LI ; Xu RAN ; Bing ZHU
Journal of Xi'an Jiaotong University(Medical Sciences) 2023;44(2):189-194
【Objective】 To investigate the effects of miR-126-3p targeting chemokine receptor 1 (CCR1) in exosomes derived from bone marrow mesenchymal stem cells (BMSC) on the proliferation, migration, and invasion of lung cancer cells. 【Methods】 BMSC cells were cultured; exosomes were extracted and identified by the exosomal marker proteins CD63 and TSG101. After exosome culture of A549 cells for different durations (0, 24, 48, and 72 h), cell survival rate was detected by CCK-8, mRNA levels of miR-126-3p and CCR1 were detected by qRT-PCR, and cell migration and invasion abilities were detected by Transwell assay. The relative expressions of CCR1, epithelial cadherin (E-cad), neural cadherin (N-cadherin), and Vimentin were detected by Western blotting. 【Results】 Exosomes had round or oval cup-shaped structures with bright edges and dark middle, with a particle size distribution of about 152 nm, expressing CD63 and TSG101 proteins. The expression of miR-126-3p in exosomes was higher than that in A549 cells. The expression of miR-126-3p was low in A549 cells and that of CCR1 mRNA was high. However, after co-culture with exosomes, the expression of miR-126-3p in A549 cells was increased, while the expression of CCR1 was decreased. A549 cells were cocultured with exosomes for 0, 24, 48, and 72 h. The survival rate, migration and invasion abilities, CCR1 gene and protein expression levels, and N-cad and Vimentin protein expression levels of A549 cells decreased gradually with the extension of culture time. The level of miR-126-3p and the expression of E-cad protein increased gradually with the extension of culture time. 【Conclusion】 The co-culture of exosomes derived from bone marrow mesenchymal stem cells with A549 cells can increase the expression level of miR-126-3p, and miR-126-3p can reduce the proliferation, migration, and invasion of A549 cells by targeting the inhibition of CCR1 expression.